Editorial orientation provided by MedAPI — not part of the coding instruction.
C19 describes a primary malignant neoplasm arising at the rectosigmoid junction, where the sigmoid colon transitions into the rectum. These tumors may share clinical and management features with both colon and rectal cancers; precise localization relative to the peritoneal reflection and anal verge can influence staging workup and treatment planning.
Common Histologies
- Conventional adenocarcinoma, including mucinous or signet-ring cell variants
- Less commonly, other primary carcinomas or rare malignant histologies
Malignant carcinoid/neuroendocrine tumors of the colon are excluded from this family and are classified separately.
Common Symptoms
- Rectal bleeding or occult gastrointestinal blood loss (K92.2)
- Change in bowel habits (R19.4), stool caliber (R19.4), constipation (R19.4), or diarrhea (R19.7)
- Tenesmus or incomplete evacuation (R15.0)
- Abdominal (R10.9), pelvic pain (R10.20), bloating (R14.0), or obstruction (K56.609)
- Iron-deficiency anemia (D50.9), fatigue (D50.9), or unintentional weight loss (R63.4)
- Incidental detection through colorectal cancer screening (Z12.11)
Diagnosis
Evaluation commonly includes colonoscopy with biopsy and assessment of the remainder of the colon for synchronous lesions. Pathology establishes histology and grade. Carcinoembryonic antigen (CEA) is often measured at baseline for prognosis and subsequent surveillance, but it is not diagnostic by itself.
Cross-sectional imaging typically evaluates regional and distant disease. Pelvic MRI or endorectal ultrasound may be appropriate when the lesion behaves anatomically as a rectal cancer, particularly when local extension and the circumferential resection margin are relevant.
Staging
Staging generally follows the colorectal TNM framework and considers:
- Depth of invasion through the bowel wall
- Regional lymph-node involvement
- Distant metastases, commonly involving the liver, lungs, or peritoneum
Because definitions of the rectosigmoid junction can vary clinically, multidisciplinary review may be needed to determine whether a tumor should follow a colon-oriented or rectal-oriented staging and treatment pathway.
Molecular Markers
Commonly assessed biomarkers include:
- Mismatch repair proteins or microsatellite instability status
- KRAS and NRAS
- BRAF, especially V600E
- HER2 in selected advanced tumors
- NTRK or other actionable alterations when clinically indicated
Results may inform hereditary cancer evaluation, prognosis, immunotherapy eligibility, and systemic treatment selection.
Common Treatments
Treatment depends on exact anatomy, stage, resectability, molecular findings, and patient factors. Options may include:
- Oncologic surgical resection with regional lymphadenectomy
- Chemotherapy for selected localized, node-positive, high-risk, or metastatic disease
- Pelvic radiation or combined chemoradiation when the tumor is managed as a rectal primary
- Targeted therapy or immunotherapy for biomarker-selected advanced disease
- Endoscopic, surgical, or palliative interventions for bleeding or obstruction
Scope Note
C19 identifies the primary anatomic site as the rectosigmoid junction, including malignant neoplasm of the rectosigmoid colon or colon with rectal involvement as reflected by the classification’s inclusion terms. It does not encode histologic subtype, grade, TNM stage, molecular profile, treatment status, or disease recurrence. It should not be used to represent a metastasis to the rectosigmoid junction from another primary site; secondary malignant disease is classified separately. Documented distant metastases require their own secondary neoplasm codes. Malignant carcinoid tumors of the colon are excluded and belong to the C7A.02- family.